Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-09-11, Stock:LLY, The news for the past five days is as follows:
2018-09-04: NEWS1: Insurance tactic drags down U.S. drug prices in 2nd qtr -analyst.NEWS2: Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised).NEWS3: Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised).NEWS4: Insurance tactic drags down U.S. drug prices in 2nd quarter -analyst.NEWS5: AstraZeneca Up This Year So Far on Favorable Pipeline Updates.NEWS6: AstraZeneca Up This Year So Far on Favorable Pipeline Updates.NEWS7: Better Buy: Pfizer Inc. vs. Eli Lilly and Company.NEWS8: Better Buy: Pfizer Inc. vs. Eli Lilly and Company.NEWS9: WisdomTree U.S. LargeCap Dividend Fund -- Insider Buying Index Registering 12.1%.NEWS10: WisdomTree U.S. LargeCap Dividend Fund -- Insider Buying Index Registering 12.1%.NEWS11: How Eli Lilly’s Elanco Performed in Q2 2018.NEWS12: AstraZeneca Up This Year So Far on Favorable Pipeline Updates.NEWS13: Better Buy: Pfizer Inc. vs. Eli Lilly and Company.NEWS14: A Look at Eli Lilly’s Neuroscience Products in Q2 2018.
2018-09-05: NEWS1: Could 2018's Best-Performing Big Pharma Stock So Far Go Even Higher Soon?.NEWS2: Could 2018's Best-Performing Big Pharma Stock So Far Go Even Higher Soon?.NEWS3: J&J Submits NDA to the FDA for Depression Drug in Adults.NEWS4: Could 2018&apos;s Best-Performing Big Pharma Stock So Far Go Even Higher Soon?.NEWS5: Lilly Announces Positive Phase 3 Results in Study of Flortaucipir PET Imaging Agent.NEWS6: Eli Lilly Has Trimmed Its Stake in Biopharma Firm Zymeworks.NEWS7: Endo (ENDP) Hits 52-Week High, Can the Run Continue?.NEWS8: Endo (ENDP) Hits 52-Week High, Can the Run Continue?.NEWS9: Invesco Dynamic Pharmaceuticals ETF Experiences Big Inflow.NEWS10: Invesco Dynamic Pharmaceuticals ETF Experiences Big Inflow.NEWS11: 3 Big Stock Charts for Wednesday: FMC, Eli Lilly and Hewlett Packard Enterprise.NEWS12: 3 Big Stock Charts for Wednesday: FMC, Eli Lilly and Hewlett Packard Enterprise.NEWS13: Boost for "made in China" medicine as Chi-Med wins key approval.NEWS14: Boost for "made in China" medicine as Chi-Med wins key approval.NEWS15: BCRX At Its Zenith, CRON Walks The Walk, TSRO To Report Data In Nov..NEWS16: BCRX At Its Zenith, CRON Walks The Walk, TSRO To Report Data In Nov..
2018-09-06: NEWS1: New Class of Migraine Drug Creates Four-Way Pharma Development Race.NEWS2: Pfizer’s PF-06651600 Receives a Breakthrough Therapy Designation.NEWS3: Lilly's Elanco unit expects IPO to raise up to $1.45 bln.NEWS4: Large Cap Pharma Stocks Staging a Comeback in Second Half.NEWS5: Large Cap Pharma Stocks Staging a Comeback in Second Half.NEWS6: Large Cap Pharma Stocks Staging a Comeback in Second Half.NEWS7: Lilly Announces Webcast to Discuss EASD Presentations.NEWS8: Eli Lilly&apos;s Elanco sets IPO terms to raise up to $1.45 billion before options.NEWS9: Elanco Announces Launch of IPO Roadshow.NEWS10: J&J Submits NDA to the FDA for Depression Drug in Adults.NEWS11: J&J Submits NDA to the FDA for Depression Drug in Adults.
2018-09-07: NEWS1: AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status.NEWS2: AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status.NEWS3: AstraZeneca&apos;s Asthma Drug Gets Breakthrough Therapy Status.NEWS4: Lilly, Teva, Pfizer & Others Await FDA Decisions in September.
2018-09-10: NEWS1: Health Care Sector Update for 09/10/2018: MYOK, ACAD, MRK, FOLD, LLY.NEWS2: Health Care Sector Update for 09/10/2018: MYOK, ACAD, MRK, FOLD, LLY.NEWS3: Eli Lilly Initiates New Trial for Taltz in Plaque Psoriasis.NEWS4: Health Care Sector Update for 09/10/2018: ACAD,MRK,FOLD.NEWS5: Health Care Sector Update for 09/10/2018: ACAD,MRK,FOLD.NEWS6: Glaxo's Nucala Suffers Regulatory Setback, Gets CRL for COPD.NEWS7: Glaxo's Nucala Suffers Regulatory Setback, Gets CRL for COPD.NEWS8: Lilly to Showcase New Data at the 27th European Academy of Dermatology and Venereology (EADV) Congress, Furthering Innovation for Patients with Complex Dermatological Conditions.NEWS9: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS10: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS11: Glaxo&apos;s Nucala Suffers Regulatory Setback, Gets CRL for COPD.NEWS12: Lilly (LLY) Hits 52-Week High, Can the Run Continue?.NEWS13: Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz® and Tremfya® in Patients with Moderate-to-Severe Plaque Psoriasis.

Answer: Decrease